Overview of Gaviscon Double Action

Property	Description
Active ingredients	Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Forms	Oral suspension, Chewable tablets
Pharmacological class	Gastrointestinal agents (Antacids and Alginate-based)
General purpose	Symptomatic relief of acid discomfort
Type	Combination formulation, Over-the-counter (OTC) medicine

Definition and Pharmacological Classification

Gaviscon Double Action is an over-the-counter (OTC) medicine defined as a combination gastrointestinal agent, recognized for its ability to provide two simultaneous therapeutic effects. This product is classified as a dual-mechanism formulation, integrating antacids with an alginate-based preparation. It is not intended to treat chronic conditions but rather provides symptomatic relief for acute discomfort, such as the burning sensation that follows meals. As a non-systemic agent, its therapeutic action is localized primarily within the upper digestive tract, with minimal components entering the systemic circulation.

Active Ingredients and Available Forms

The formulation is a combination product containing three distinct active ingredients: Calcium Carbonate and Sodium Bicarbonate (the antacids), and Sodium Alginate (the physical agent). Sodium Alginate is derived from brown seaweed, a unique feature that enables the physical mechanism of protection. This preparation is intended for oral administration and is differentiated by its availability in both a highly viscous oral suspension (liquid formulation) and solid chewable tablets, offering patient choice in delivery form.

General Purpose and Dual-Action Relief

The general purpose is to rapidly achieve and sustain symptomatic relief for acid-related discomfort using a dual approach. The included antacid components provide rapid neutralization of stomach acid quickly after ingestion. Concurrently, the Sodium Alginate component reacts with gastric acid to form a protective, low-density gel layer, known as the alginate raft. This alginate-antacid combination creates a persistent physical barrier in the stomach, which prevents the movement of acidic material back into the esophagus.

What side effects are possible with Gaviscon Double Action?

Possible Side Effects and Safety Information

The safety profile for this medicine is characterized by a limited spectrum of adverse reactions, with most reported events falling into the Very Rare frequency classification, as detailed in official regulatory documents. These officially listed reactions are primarily related to Immune System Disorders.

Officially Documented Adverse Reactions

Adverse Reaction Type	Frequency Classification	System Organ Class (SOC)
Hypersensitivity Reactions (e.g., urticaria, bronchospasm)	Very Rare (<1/10,000)	Immune System Disorders
Anaphylactic/Anaphylactoid Reaction	Very Rare (<1/10,000)	Immune System Disorders
Metabolic Effects (e.g., Hypercalcaemia, Alkalosis, Constipation)	Not Known	Metabolism and Nutritional Disorders/Gastrointestinal Disorders

Population-Specific Safety Considerations

The presence of sodium and calcium carbonate in the formulation requires specific caution notes in the regulatory label for certain individuals. Caution is advised for patients with impaired renal function or those on a highly restricted salt diet. Similarly, caution is noted when treating patients with pre-existing conditions involving hypercalcaemia or nephrocalcinosis due to the calcium component.

Safety Patterns Related to Use

Official labeling documents state that certain systemic adverse effects, such as Milk-alkali Syndrome and severe Alkalosis, are generally associated with prolonged use or the intake of larger than recommended dosages. As a high-level safety constraint, the medicine's antacid properties require a two-hour time interval between its intake and other oral medications, as it may interfere with their absorption.

Overdose and Emergency Response

Overdose Scope

Property	Official Regulatory Statement
Documented overdose presentations	Acute symptoms are generally documented as minor, including abdominal discomfort and abdominal distension.
Physiological systems affected	Gastrointestinal system (acute); Metabolic system (chronic high-dose use), leading to Alkalosis and Hypercalcaemia.
Dose-related or exposure-related factors	Severe outcomes, such as Milk-alkali syndrome, are associated with the use of larger than recommended dosages for prolonged periods.
Population-specific overdose notes	The high sodium content requires particular consideration for individuals on a low salt diet or with renal impairment.
Emergency-response statements	The mandated management in the event of an overdose is the administration of symptomatic treatment.
When medical help is required	Urgent help-seeking is tied to the risk of severe chronic effects following prolonged, excessive intake, rather than typical acute ingestion.

Overdose Classifications (High-Level)

Classification	Official Regulatory Statement
Severity classification	Acute overdose is generally classified as presenting with minor symptoms.
Overdose-context constraints	High-dose risks are explicitly linked to the calcium carbonate component when taken excessively over a sustained duration.

Resulting Overdose Structure

Official overdose statements:

Symptoms of acute overdose are documented as likely to be minor, including abdominal discomfort and abdominal distension.
The mandated procedure in the event of an overdose is to provide symptomatic treatment.
Severe outcomes, such as Milk-alkali syndrome, Alkalosis, and Hypercalcaemia, are associated with prolonged ingestion of larger than recommended dosages.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile primarily through two risk vectors: minor, self-limiting acute gastrointestinal effects, and systemic metabolic disturbances resulting from chronic overuse. The official management instruction is limited to the provision of symptomatic treatment, and specific mandatory triggers for seeking immediate medical help are generally tied to the risk of severe chronic effects.

Therapeutic Uses of Gaviscon Double Action

What Gaviscon Double Action treats: main uses and benefits

This medicine is commonly used where additional symptomatic support is needed for conditions presenting with acute or disruptive symptom patterns related to acid reflux.

This product is relevant for managing symptoms related to irritative states, focusing primarily on heartburn, acid regurgitation, and indigestion (dyspepsia). It is applied in situations involving certain distressing symptoms of hyperacidity, which are conditions characterized by periods of heightened symptoms. It helps address symptom clusters that create noticeable physiological strain and is relevant for easing symptoms associated with epigastric distress, supporting improved day-to-day comfort.

The medication is commonly used to help with symptoms that interfere with daily functioning and become more disruptive during flare-ups, such as those that appear after meals or manifest as nocturnal heartburn. It is considered relevant for easing acid reflux symptoms during pregnancy, assisting with maintaining functional stability during symptomatic phases.

The goal is to provide supportive relief during symptomatic episodes, assisting individuals in coping more steadily with difficult manifestations.

Quick Fact: Relief for Heartburn and Indigestion
Used to manage acute burning and discomfort associated with acid reflux and hyperacidity in common scenarios like post-meal or nocturnal symptom onset.
Supports individuals, including pregnant individuals, by easing the overall symptom burden.

Regulatory References

MHRA Public Assessment Report

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility for Gaviscon Double Action is determined by regulatory agencies based on age, existing medical conditions, and sensitivity to the product’s components. The regulatory documentation classifies populations into allowed, restricted, and contraindicated groups.

Category	Regulatory Status
Populations for whom use is allowed	Adults and children aged 12 years and over are the standard eligible populations. No dose modifications are necessary for the elderly or those with hepatic impairment.
Populations for whom use is contraindicated	Individuals with known or suspected hypersensitivity to any active substance or excipient must not use the medicine. It is also contraindicated in cases of severe renal insufficiency or hypophosphatemia.
Pregnancy and lactation eligibility	May be used during pregnancy and can be used during breastfeeding, if clinically needed, as adverse effects on the fetus or infant are not documented in controlled studies.

Eligibility-Related Restrictions

Use in children younger than 12 years of age is not generally recommended and should be given only on medical advice. Caution is required when treating patients on a highly restricted salt (sodium) diet, or those with conditions sensitive to calcium content, such as hypercalcaemia or recurrent calcium containing renal calculi.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing clear absolute contraindications for specific severe metabolic and organ dysfunctions, while confirming eligibility for adults and adolescents. Other patient groups are defined by conditions requiring caution or medical oversight.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents emphasize that this product has the potential to reduce the absorption and therefore the efficacy of other orally administered medicines. This interaction is mechanistic, stemming from the product's action in the digestive tract.

To mitigate this effect, a strict timing constraint is required: any other orally taken medicine must be administered 2 hours before or 2 hours after Gaviscon Double Action. Adherence to this spacing rule is essential to ensure that the co-administered drug can be absorbed correctly.

This required timing separation applies to several therapeutic categories and specific compounds, as outlined in official labeling. These include:

Category/Compound
Tetracyclines
Digoxin
Fluoroquinolones
Iron salts
Thyroid hormones
Estramustine
Bisphosphonates
Gabapentin
Ketoconazole
Atazanavir
Lanzoprazole
Fexofenadine
Chlorpromazine
Penicillamine
Sulphonylureas

The constraint to separate administration by two hours is the primary safety requirement relating to drug interactions for this product, covering all medicines whose systemic availability could be clinically lowered by simultaneous use.

Mechanism of Action

Chemical Modulation and Rapid pH Control

This mechanism involves the immediate chemical neutralization of H^+ ions (Gastric Acid) by Calcium Carbonate and Sodium Bicarbonate within the stomach lumen. This non-systemic reaction rapidly elevates the pH of the gastric contents, leading to the functional inactivation of Pepsin. This domain results in a transient elevation of the luminal pH, modulating the chemical profile of the gastric contents.

️ Mechanical Barrier Formation and Reflux Impairment

The second domain centers on the physical barrier construction by Sodium Alginate. Upon contacting gastric acid, the alginate precipitates and, using the Ca^2+ ions and CO2 gas generated by the antacids, rapidly forms a buoyant, cohesive gel known as the alginate raft . This raft floats atop the stomach contents, physically impeding the retrograde flow of acidic material and reinforcing the upper digestive tract's mucosal barrier against chemical activity.

Mechanistic Synergy for Sustained Action

This formulation utilizes a pharmacodynamic synergy where components contribute to the function of the physical barrier. The antacid components are essential for forming the raft by providing the Ca^2+ needed for cross-linking (raft strength) and the CO2 needed for buoyancy. This integrated chemical and physical action establishes a physically sustained and cohesive barrier against the chemical activity of the upper gastrointestinal system.

Dosage and Administration Information

How to Use Gaviscon Double Action

This section describes the administration and usage patterns for Gaviscon Double Action, focusing strictly on procedural instruction rather than clinical advice or therapeutic claims. The medicine is intended for the oral route of administration.

Official Dosing and Frequency

Feature	Standard Instruction
Dosing Schedule (Adults & Children 12+)	Suspension: 10 ml to 20 ml per dose. Tablets: Two to four tablets per dose.
Timing in Relation to Meals	Doses are to be taken after meals and at bedtime.
Maximum Frequency	The maximum administration is limited to up to four times per day.

Administration Requirements

Standard instructions establish specific procedures for ingestion and scheduling:

Chewable tablets must be chewed thoroughly before being swallowed.
A time-interval of 2 hours should be observed between taking this product and the administration of other oral medicines. This is required due to the presence of antacid components.

Population-Specific Use and Duration

Administration to children under 12 years should occur only on medical advice. Older adults (Elderly) require no dose modifications. Furthermore, the product may be used during pregnancy and lactation if clinically necessary. The medicine is intended for short-term, symptomatic use; if symptoms persist or continuous treatment is required for more than 7 days, medical advice should be sought.

Procedural Rule	Instruction
Missed Dose	Do not take a double dose to compensate for the missed dose.
Duration Limit	Seek advice if use exceeds 7 days continuously.

Recent Clinical Evidence

Research evidence / Overview of studies for Gaviscon Double Action

Evidence for Acute Symptomatic Relief (Heartburn, Regurgitation, and Dyspepsia)

The primary body of research on Gaviscon Double Action was studied in contexts involving acute or episodic symptom patterns related to acid discomfort, specifically heartburn, acid regurgitation, and dyspepsia (indigestion). The clinical evidence base largely relies on short-term randomized, double-blind, placebo-controlled trials (RCTs). This means that groups of volunteers were given either the active medicine or an inactive placebo for a defined period, and neither the participants nor the researchers knew who received which treatment.

These trials research examined how quickly symptoms changed over time and how they were reported by the participants themselves. The outcomes monitoring focused on physical discomfort, often using specific questionnaires like the Reflux Disease Questionnaire (RDQ), which was studied for tracking changes in heartburn and indigestion scores. Findings describe patterns observed in the studies where research explored differences in symptom score measurements between the participants receiving the medicine and those receiving placebo over the typical 7-day follow-up duration.

Trial Design and Comparison to Placebo

In the controlled settings of clinical trials, the product was evaluated in research exploring short-term symptom changes. These studies were structured so that research was designed to explore differences in reported changes between the groups receiving the medicine versus the placebo. The results apply only to the populations studied and reflect the specific, short-term conditions under which the research was conducted.

Evidence in Specific Populations

For most patient groups, the research evidence available is not uniform. The largest randomized studies were conducted in adult populations experiencing general, symptomatic GERD. Data for certain groups remain insufficient. For example, the medicine was observed in some studies relevant in research contexts involving reflux symptoms during pregnancy. This evidence contributes to the broader evidence landscape, but the full range of evidence for these special populations is limited.

Evidence Gaps and Areas of Uncertainty

One key limitation is the focus on short-term changes. While some observational studies extend to a few weeks, long-term effects are not fully established by similar large-scale randomized trials. The limited follow-up durations mean that it is not yet clear whether the product is associated with sustained symptom changes beyond a typical week of use. Additionally, comparative evidence is lacking from trials that directly pit this specific dual-action product against the full range of alternative prescribed treatments for acid-related symptoms.

Frequently Asked Questions (FAQ)

Common questions about Gaviscon Double Action (FAQ)

Q: How quickly does Gaviscon Double Action start working after taking it?

Studies and official product information indicate that the medicine reacts rapidly with stomach acid. The antacid components are designed to provide rapid relief from symptoms of heartburn and indigestion upon ingestion, according to regulatory information.

Q: What is the expected duration of relief from a single dose of Gaviscon Double Action?

According to official regulatory documents, the protective gel raft that forms in the stomach is demonstrated to impede the movement of acidic material (reflux) for a duration of up to 4 hours.

Q: Can Gaviscon Double Action cause constipation?

Constipation is listed as an officially documented adverse reaction, although its frequency is classified as 'Not Known' in regulatory texts. If any side effects are experienced while using the medicine, it is recommended to discuss them with a healthcare professional.

Q: Is it true that Gaviscon Double Action creates a 'raft' in the stomach?

Yes, official product information confirms this. Upon coming into contact with stomach acid, the alginate component precipitates and rapidly forms a buoyant, cohesive gel known as the alginic acid gel raft. This physical barrier floats atop the stomach contents.

Q: What evidence is there that Gaviscon Double Action works better than basic antacids?

The dual mechanism of action is supported by studies. However, the regulatory documents also note that comparative evidence is lacking from large-scale trials directly comparing this specific product against all alternative acid-related treatments.

Q: Is the tablet form as effective as the liquid form of Gaviscon Double Action?

Both the liquid (oral suspension) and the chewable tablets contain the same active ingredients and are indicated for the same symptoms (heartburn and indigestion). Regulatory text does not explicitly compare the two forms, which are both indicated for the same symptoms.

Q: What is the typical time frame to see improvement when using Gaviscon Double Action?

The product is intended for short-term, symptomatic use. If symptoms persist or do not improve after 7 days of continuous use, the official guidance is to seek medical advice.

Q: Is it normal to feel a chalky taste after taking the liquid Gaviscon Double Action?

The medicine contains active antacid ingredients, such as calcium carbonate, and other components (excipients). While a specific 'chalky taste' is not listed as a side effect, the ingredients may contribute to the taste and sensation experienced upon ingestion.

Q: Can Gaviscon Double Action cause bloating or gas?

Taking excessive doses of the medicine may lead to feelings of bloating, according to official labeling. Also, as a combination of antacids and alginate, its reaction in the stomach may generate gas (carbon dioxide) which could lead to temporary bloating or belching.

Q: Can you crush or chew the Gaviscon Double Action tablets?

Official administration instructions only require that chewable tablets be chewed thoroughly before swallowing. It is important to adhere to the administration instructions provided on the label.

Q: Why do people use Gaviscon Double Action for indigestion?

The medicine is officially indicated for the treatment of symptoms related to acid discomfort. This includes common conditions like heartburn, acid regurgitation, and indigestion (dyspepsia).

Q: Does Gaviscon Double Action contain sugar or artificial sweeteners?

The official list of ingredients (excipients) for some forms may include sweeteners like saccharin sodium, acesulfame K, and aspartame (a source of phenylalanine). It is advisable for individuals to check the full list of excipients on the specific product packaging for certainty.

Q: Can I take Gaviscon Double Action with milk?

Official safety warnings advise against taking this product with large amounts of milk or milk-products. This is because combining it with milk may increase the risk of rare, but serious, metabolic side effects like Milk-alkali Syndrome.

Q: Does Gaviscon Double Action help with non-acid reflux?

The mechanism of action is primarily focused on neutralizing stomach acid and forming a barrier against the reflux of acidic material. The stated indication is for acid-related symptoms.

Q: What should I do if I accidentally take too much Gaviscon Double Action?

Official product information states that symptomatic treatment should be given in the event of an overdose. If too much is taken, temporary symptoms like bloating may occur. Official guidance suggests consulting a healthcare professional in the event of an overdose.

Q: Can I take Gaviscon Double Action after eating a large meal?

Official administration instructions state that the medicine is to be taken after meals and at bedtime. The regulatory documents do not specify any restrictions based on the size of the meal.

Q: Are there different flavors available for Gaviscon Double Action?

Yes, different formulations and presentations of the product are available with various flavorings, such as Mint and Aniseed, as detailed in regulatory documents.

Q: What is the shelf life of Gaviscon Double Action once the bottle is opened?

For the liquid suspension, the product must be used within six months of opening the bottle. The specific shelf life for the chewable tablets after opening may vary depending on the product presentation.

Q: Are there any dietary restrictions while using Gaviscon Double Action?

Official labeling requires caution for patients on a highly restricted salt (sodium) diet or those with high blood pressure, and for patients with conditions sensitive to calcium content. It is also advised against taking it with large amounts of milk products.

Q: Is Gaviscon Double Action gluten-free?

Official product information for certain regulatory jurisdictions and formulations indicates the product does not contain gluten. It is important to verify the full list of excipients on the specific product packaging.

Q: Can Gaviscon Double Action be used for gas pain?

The medicine is primarily indicated for symptoms of heartburn and indigestion. While it may help alleviate some bloating and discomfort due to its antacid properties, the medicine's stated purpose is for acid-related symptoms.

Q: What happens if I take Gaviscon Double Action on an empty stomach?

Official guidance advises that the dose should be taken after meals and at bedtime to ensure optimal performance of the alginate raft. Taking it on an empty stomach deviates from the regulatory recommendations for use.

Q: Does Gaviscon Double Action interact with aspirin?

Like other antacids, the medicine has the potential to reduce the absorption of other oral drugs. A 2-hour time interval is required between the intake of Gaviscon and any other orally administered medicine, including aspirin.

Q: Can I take Gaviscon Double Action if I'm taking blood pressure medication?

A 2-hour time interval is required between the intake of Gaviscon and any oral medication, which includes most blood pressure medications, to avoid interference with drug absorption. Additionally, caution is noted for patients with high blood pressure due to the sodium content.

Q: Can I take Gaviscon Double Action if I am lactose intolerant?

Lactose is not typically listed as an active ingredient or common excipient for this product. However, as excipients can vary by form and country, it is advisable to verify the full list of excipients on the specific product packaging.

How should Gaviscon Double Action be stored and disposed of?

Storage and Disposal Requirements for Gaviscon Double Action

Official regulatory labeling dictates strict storage and disposal requirements to ensure product stability and environmental safety.

Storage Conditions

The medicine must be stored below 30 C and should not be refrigerated or frozen. Both the suspension and tablets must be kept out of the sight and reach of children.

Liquid Suspension: Store in the original container. Once opened, the suspension must be used within six months.
Chewable Tablets: Store in the original package to protect from moisture.

Disposal

Expired or unused Gaviscon Double Action must not be disposed of in household waste or wastewater. For proper disposal, the product should be returned to a pharmacist to help protect the environment.

Gaviscon Double Action